1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,314 | 0,329 | 13:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Oncodesign Precision Medicine (OPM): OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments | 560 | Business Wire | Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology) Significant progress with OPM-201: independent validation... ► Artikel lesen | |
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| 03.03. | Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson's Disease | 595 | Business Wire | The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson's disease and the execution of long-term toxicology study including... ► Artikel lesen | |
| 08.01. | Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases | 437 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant... ► Artikel lesen | |
| 29.12.25 | Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics | 415 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 06.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.11.2025 | 346 | Xetra Newsboard | Das Instrument ZC0 NO0012780958 STAINL.TANKERS NK 10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.11.2025 und ex Kapitalmassnahme am 07.11.2025 The instrument ZC0 NO0012780958 STAINL.TANKERS NK... ► Artikel lesen | |
| 14.10.25 | Oncodesign Precision Medicine: OPM Obtains Development Grants From the Bourgogne Franche-Comté Region | 546 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 09.10.25 | Oncodesign Precision Medicine: OPM Publishes Its 2025 Half-Yearly Report | 555 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 25.09.25 | Oncodesign Precision Medicine: OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkinson's Research | 431 | Business Wire | OPM will contribute its unique expertise in kinase inhibitor development and its Nanocyclix®-derived compound OPM-201 to the LITE program OPM will leverage the LITE consortium to accelerate... ► Artikel lesen | |
| 31.07.25 | Oncodesign Precision Medicine: OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position | 729 | Business Wire | The REVERT Phase 1b/2a clinical trial evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 has been submitted to the Swiss regulatory (Swissmedic) and ethics (Swiss ethics)... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,19 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,300 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,12 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 18,810 | -0,05 % | Erasca closes $632.5 million public stock offering | ||
| TARSUS PHARMACEUTICALS | 56,33 | +0,14 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,455 | +0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,310 | -0,08 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,765 | -0,03 % | BMO initiates Trevi Therapeutics stock at Outperform, $36 target | ||
| HEMAB THERAPEUTICS | 49,390 | 0,00 % | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | ||
| KYMERA THERAPEUTICS | 111,11 | +0,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 304,26 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| QIAGEN | 35,050 | -2,69 % | Evotec, Formycon oder Qiagen? Diese Aktie kann sich jetzt verdoppeln | Der europäische Biotech-Sektor bleibt in Bewegung: Unternehmensnachrichten, Partnerschaften und Analysteneinschätzungen sorgen derzeit für teils deutliche Kursausschläge. Bei Evotec, Formycon und Qiagen... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,800 | 0,00 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen | |
| VOR BIOPHARMA | 17,450 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,230 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |
ONCODESIGN PRECISION MEDICINE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,034 (+12,14 %) liegt der Kurs bei 0,314 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCODESIGN PRECISION MEDICINE SA finden Sie auf Wallstreet Online.